Evidence map›Paper›PMID 37071474›Full record

ArticleThe Journal of clinical investigation2023

KIR-HLA interactions extend human CD8+ T cell lifespan in vivo.

Yan Zhang, Ada Wc Yan, Lies Boelen, Linda Hadcocks, Arafa Salam, Daniel Padrosa Gispert, Loiza Spanos, Laura Mora Bitria, Neda Nemat-Gorgani, James A Traherne and 9 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Neuron-reactive KIRNature communications · 2025
    Article
  4. Article
  5. Article
  6. Deuterated water (Frontiers in immunology · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Negativity begets longevity in T cells.The Journal of clinical investigation · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 2 countries.

Yan ZhangInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Ada Wc YanDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Lies BoelenDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Linda HadcocksInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Arafa SalamInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Daniel Padrosa GispertDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Loiza SpanosInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Laura Mora BitriaDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Neda Nemat-GorganiDepartment of Structural Biology and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
James A TraherneDepartment of Pathology, University of Cambridge, Cambridge, United Kingdom.
Chrissy RobertsDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Danai KoftoriDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Graham P TaylorDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Daniel FortonInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Paul J NormanDepartment of Structural Biology and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Steven Ge MarshAnthony Nolan Research Institute, Royal Free Hospital, London, United Kingdom.
Robert BuschSchool of Life and Health Sciences, University of Roehampton, London, United Kingdom.
Derek C MacallanInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Becca AsquithDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Imperial College London · GBSt George's, University of London · GBAnthony Nolan · GBImperial College Healthcare NHS Trust · GBLondon School of Hygiene & Tropical Medicine · GBStanford University · USUniversity of Cambridge · GBUniversity of Colorado Denver · USUniversity of Roehampton · GB

Funding

Insights Into Immune-Related Diseases Born from Population GenomicsU01AI090905 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Paul John Norman · 2010 to 2026
$10.9M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
Department of HealthMedical Research Council G1001052Medical Research Council J007439NIAID NIH HHS U01 AI090905NIDDK NIH HHS P30 DK116073Wellcome TrustWellcome Trust 103865Z/14/Z
6 · The paper itself

Abstract

BACKGROUNDThere is increasing evidence, in transgenic mice and in vitro, that inhibitory killer cell immunoglobulin-like receptors (iKIRs) can modulate T cell responses. Furthermore, we have previously shown that iKIRs are an important determinant of T cell-mediated control of chronic viral infection and that these results are consistent with an increase in the CD8+ T cell lifespan due to iKIR-ligand interactions. Here, we tested this prediction and investigated whether iKIRs affect T cell lifespan in humans in vivo.METHODSWe used stable isotope labeling with deuterated water to quantify memory CD8+ T cell survival in healthy individuals and patients with chronic viral infections.RESULTSWe showed that an individual's iKIR-ligand genotype was a significant determinant of CD8+ T cell lifespan: in individuals with 2 iKIR-ligand gene pairs, memory CD8+ T cells survived, on average, for 125 days; in individuals with 4 iKIR-ligand gene pairs, the memory CD8+ T cell lifespan doubled to 250 days. Additionally, we showed that this survival advantage was independent of iKIR expression by the T cell of interest and, further, that the iKIR-ligand genotype altered the CD8+ and CD4+ T cell immune aging phenotype.CONCLUSIONSTogether, these data reveal an unexpectedly large effect of iKIR genotype on T cell survival.FUNDINGWellcome Trust; Medical Research Council; EU Horizon 2020; EU FP7; Leukemia and Lymphoma Research; National Institute of Health Research (NIHR) Imperial Biomedical Research Centre; Imperial College Research Fellowship; National Institutes of Health; Jefferiss Trust.

Indexed as

Killer Cells, NaturalLongevityAnimalsCD8-Positive T-LymphocytesHumansLigandsMiceReceptors, KIRUnited StatesLigandsReceptors, KIRAdaptive immunityGenetic variationImmunologyT cells

Identifiers

PMID37071474
PMCPMC10266773
OpenAlexW4366235043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.